Member Info for mol42

Whilst i have still to find that lpldl has passed anvisa

ayalla are presenting at an upcoming summit

Check out our face-to-face lecture on “The risks of Cardiometabolic Syndrome and the benefits of dietary supplementation in preventing the development of cardiovascular complications” on 05/31 at 11:30 am at NIS Application Trends.

The lecture will bring data on the incidence of Cardiometabolic Syndrome, highlighting the risk factors involved in this process, the implications they may have for the health of the population and how food supplementation can contribute and bring benefits, which help in the control of the Syndromes Metabolic and in preventing the development of cardiovascular complications.

Some ingredients that present scientific literature that prove and highlight the benefits of food supplementation for the control of Cardiometabolic Syndrome will be highlighted, aiming to be a very effective alternative for the reduction of complications and incidence of potential cases for cardiovascular risk factors.

https://nisummit.com.br/en/inicio-2/

mol

Https://www.sunday.de/en/flora-cardio-capsules.html

things seem to be picking up - with CholbiomeCH, Denk Ingredients, Cholerice and Tensred Plus in recent weeks

mol

Cheers Elrico

mol

Perhaps nobody on here recognises what my moniker means

mol

I can assure you that I have little to learn re companies on aim and their BOD

Together with commentators / experts/ and other assorted posters

The difference is I call out the BOD and also the happy clappers on occasion

Mind I’m also not endeavouring to build a subscriber base - albeit good luck with your business

it.s mol btw

mol

Off topic

but i've now realised that lse time stamp is not on BST

mind why we as in UK still adopt same is a topic for discussion - albeit not on this bb

amongst a number of other subjects currently running in the media

mol

Btw made a mistake all on reviewing posts this evening

material revenues well into 2025

i'll still be here

not sure how many of the recent new posters will be nor any of the happy clappers

mol

Whilst what Cath may have discovered can be described as exceptional

what SA and his subsequent mate have done since cannot be described in any way as exceptional other than of course

their over-inflated salaries and jees i even noted that our company has since employed an assistant to Manprit a while ago

why does he need accounting help with the recording of our very small number of transactions?

mol

The heading of this thread should give a clue to what I was referring to - the recent announcements by our BOD

and their expectations/beliefs etc - their recent performance could not be said to endear confidence imo

a reminder to all that Cath started the conversation and negotiations with Croda -prior to SA's involvement

Dr Cath O'Neill, CSO of SkinBioTherapeutics, said:

"To have secured our first agreement with such a prestigious partner demonstrates the value of SkinBioTherapeutics' offering. This deal offers the potential for SkinBiotix™ to be incorporated into some of the world's biggest cosmetics brands, which was always the vision that we had for the technology. I am really pleased to have initiated the discussions and negotiations and to have worked with Stuart to get it to completion. This is an exciting step forward for SkinBioTherapeutics."

Stuart Ashman, CEO of SkinBioTherapeutics, said:

"The focus of this year has been on commercialisation, therefore, we are delighted that the first announcement has been a significant deal with a world-leading company such as Croda and being able to utilise the expertise within Sederma. This partnership brings together our innovation in the microbiome space and Sederma's track record of developing world-class cosmetic ingredients. As we have stated before, we intend to build a significant portfolio around our core technology across multiple sectors to create further value for our shareholders - this deal with Croda is just the beginning."

Think Cath had more to do with deal than SA

Jul 19 transistion to CEO and then to Nov 19 deal - and all down to him - hmm

anyway apparently in 2019 that was only the beginning of commercialisation

well of course we have now c 80k revenues from......

mol

10 May 2023

The further studies are expected to take an additional three to four months, and would run from November 2023 through to Q1 2024. Any additional benefits identified from these studies would enable Croda/Sederma to add to the commercial opportunity for SkinBiotix as an active ingredient and could lead to enhanced claims and therefore a higher price point in market. The costs of these additional studies will be paid for by Sederma.

16 Dec 2022

In November 2019 the Company signed a commercial agreement with Croda International Plc (“Croda”),

and its speciality bioactive ingredient manufacturer, Sederma, for the development and commercialisation

of a new active skincare cosmetic ingredient, incorporating the SkinBiotix® technology. The Company

continues to engage with Croda and Sederma with regards to the commercialisation phase of the

Skinbiotix® product, with the next update meeting between Croda and the Company the scheduled for

January 2023. The product development timing is controlled by Croda, however the Directors believe that

the product launch will occur in 2023 and thus the Directors expect some initial royalties revenues from

Croda to commence in 2023

29 Mar 2022

Croda is engaging with its VIP clients about SkinBiotix as an active cosmetic ingredient; the Group continues to anticipate licensed royalty revenue generation by the end of 2022.

Whilst I acknowledge Croda/Sederma paying for this, for which we have handed over complete control and timing, I found it interesting to say the least that the further additional studies will only commence in Nov 2023 - why? and was it only in the Jan 23 meeting that company found out or even after that?

any initial revenues from this commercial agreement can be pushed post qtr1 2024 imo and anything approaching material revenues well into 2024

mol

Ah must now be a lse thing after their recent update

jees a bit more effort then guys - lol

mol

Keep forgetting to just remove the s on http when posting

http://www.nutritionaloutlook.com/view/how-can-supplements-stay-relevant-in-an-evolving-weight-management-space-

mol

How can supplements stay relevant in an evolving weight-management space?

https://www.nutritionaloutlook.com/view/how-can-supplements-stay-relevant-in-an-evolving-weight-management-space-

Gut Instincts

Approaching wellness via the microbiome is a specialty at OptiBiotix Health Plc (York, UK), and as CEO Stephen O’Hara says, “The challenge with weight management is to steer the conversation in a new direction with alternatives that offer no reported side effects but that deliver the same results” as do pharmaceuticals like Ozempic.

For example, the company’s SlimBiome, a patented, mineral-enriched prebiotic fiber complex, “gently expands in the stomach to help consumers feel fuller longer,” O’Hara claims. The ingredient also attenuates blood-glucose levels and reduces craving—all actions seen with semaglutide.

But the fiber complex actually modifies the microbiome, O’Hara says, “to increase the number of microbes associated with lean body shape.”

According to one double-blind, placebo-controlled study carried out by Oxford Brookes University7, SlimBiome reduced hunger by 10%, food cravings by 11%, and food intake by 49%. “A second study8 by the University of Roehampton demonstrated a 21% reduction in food cravings and a 26% improvement in mood,” O’Hara adds. “It also showed that 90% of volunteers lost weight, reduced their body fat, and exhibited reductions in hip and waist circumferences.”

In comparison to injectable drugs, SlimBiome generated no side effects in either study, and it appears to spare muscle even at the expense of body fat—a hedge against reported cases of muscle loss and wastage associated with semaglutide use, O’Hara notes. “So while there’s no simple path to weight loss,” he concludes, “there are safe, effective, and sustainable alternatives that help consumers help themselves.”

mol

OptiBiotix Health Plc (‘OptiBiotix’), a scientific pioneer in microbiome modulating solutions, has announced the launch of its new WellBiome® solution for the wellbeing and healthy ageing market.

The direct-to-consumer pack WellBiome® will launch on the OptiBiotix.online store to coincide with the company’s visit to Vitafoods Europe, taking place this month in Geneva, Switzerland.

As a patented, mineral-enriched prebiotic multi-fibre complex, WellBiome® promotes gut microbiome diversity and gut barrier integrity by enriching the health positive bacteria in the gut. Research studies suggest that consuming a combination of different fibres like of those within WellBiome® can increase microbiome diversity more than a single fibre product. The consumer pack contains 30 flavourless sachets, so that it can be added to any food or beverage ingredient, which is easily added to a daily routine, and features just 11 calories per serving.

https://optibiotix.com/optibiotix-to-launch-new-wellbiome-solution-for-wellbeing-and-healthy-ageing-consumer-market-at-vitafoods-europe-2023/

mol

In response to the Monacolin K discussion previously on this BB

To support food brands, retailers and consumers in making the switch from Monacolin K to another alternative solution, CholBiome®CH. contains two active ingredients in a bi-layer tablet – the company’s patented probiotic backed by multiple independent studies, Lactobacillus plantarum LPLDL®, and Plant Sterols / Stanols (PSS). These combine synergistically to support the reduction of both internal and dietary cholesterol levels via its dual action cholesterol reducing formula.

https://optibiotix.com/probiotix-health-launches-cholbiomech-at-vitafoods-europe/?utm_source=twitter&utm_medium=social&utm_campaign&utm_content=ap_tr3ap9n9ih

Steen commented

This new allergen and GMO-free innovation delivers a dual mechanism of action, where the award-winning ingredient LPLDL acts on the internal cholesterol to produce enzymes that break down bile salts. This encourages the liver to remove cholesterol from the blood to replenish required levels and maintain the body’s bile salt pool. Through the secondary action, PSS reduces dietary cholesterol absorption and promotes excretion.

Due to the inclusion of PSS, CholBiome®CH can claim to contribute to the maintenance of normal blood cholesterol levels, as backed by EFSA4.

“High levels of cholesterol have been commonly tackled by approaches that come with multiple undesirable side effects,” continued Andersen. “Yet LPLDL offers a scientific, side-effect free alternative to improve cardiovascular health. The naturally occurring probiotic strain has demonstrated its efficacy in several human studies showing that it can effectively lower total cholesterol and ‘bad’ LDL cholesterol, while increasing ‘good’ HDL cholesterol. As a leader in the microbiome modulation area, consumers and those in the industry can rest assured that we continuously expand the clinical studies supporting the efficacy of CholBiome and LPLDL.”

mol

Thx Aquae for your recent posts and relative optimism - obviously because you are currenty in

I, as you know, continue to hold whilst having written off my investment/gamble in my portfolio to all intents and purposes

It is extremely unlikely that i will ever recover my initial and subsequent gamble/investment

but that was my decision - tis aim afterall - mind he ( SOH) in his absolute genius decided to go to aquis as well

I now consider that S O'Hara, and his concert parties, have lost all credibility and the up coming investor meet will just

be rinse and wash - as usual

his claim re being a founder of another company in his disclosure at outset of opti doesn't btw seem to agree with companies house records

It is with a heavy heart that i post this - but even at this price I won't be adding nor recommending anyone else

jees it was only in dec he was spouting about tasting coming sweetbiotix products in the new year

and here we are in May

you can all put as many questions as you like but they won't change the position

I've only ever lost once completely, on an aim share, but i don't have the TIME now to go into detail - lol

I continue to hold because I hope to recover more of my gamble/losses than the value of my investment but .......

mol

https://www.psoriasis-association.org.uk/forums/treatments

Well done Toyin - let’s see reaction

mol

mind doesn't really matter what i think

let's see what the sales are in the coming months with these new formulations - perhaps steen had an input to presentation and perhaps a slight tweak?

anyway we should perhaps be on pbx board

bw aquae et al

mol

lol

thx aquae

still think a bad choice of code (mind probably because I spend more time on website than any new buyers or even any buyers) and still not convinced brand new

mol

eg

https://lpldl.com/wp-content/uploads/2021/01/CholBiomeVH-A4-Leaflet-2020.pdf

https://www.nutritioninsight.com/news/probiotix-health-eases-hypertension-with-new-probiotic-vitamins-supplement.html

mol